Skip to main content
Donate

Join Our Community

Join our community and receive :

  • Angelman syndrome research education and updates.

  • Insight on clinical trials and observational studies.

  • Latest foundation news and family resources.

  • Community spotlights and events.

  • Opportunities to get involved in the community.

For a full disclosure of how your email is used, please visit our Privacy Policy page.

Sign Up Today

FAST Angelman Syndrome News

Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Investing in the Future of Angelman Syndrome Research: FAST Partners with ASGCT to Support Early-Career...

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

FAST Announces Funding For First Innovative Seed Grant

Leading Neurology and Rare Disease Expert Dr. Nick France Joins FAST Board

More Than a Seat at the Table: FAST’s Role in Shaping the Future of Angelman Syndrome at ASGCT 2025

CAN Spotlight: Kettlebells for Kayleigh Fundraiser in Germany

CAN SPOTLIGHT: Skating Angels Charity Ice Hockey Tournament

MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy ...

FAST Speaks at the 2025 MENA Congress for Rare Diseases

Expanding the Pre-Clinical Research Landscape for Angelman Syndrome

Oak Hill Bio to continue the development of rugonersen, an investigational ASO previously owned by Roch...

CAN Spotlight: Bike 4 Briar Starts May 27th!

FAST-funded researcher highlights the involvement of UBE3A in different neurodegenerative diseases

Progress for Angelman Syndrome Relies on a Strong NIH and FDA

IONIS REVEAL Phase 3 Clinical Trial Update

Exciting Announcement: Launch of Our New Electronic Journal

Community Update: New Insights into Health and Prevention in Angelman Syndrome

The Economic Burden of Caring for Individuals with Angelman Syndrome

Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Investing in the Future of Angelman Syndrome Research: FAST Partners with ASGCT to Support Early-Career...

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

FAST Announces Funding For First Innovative Seed Grant

Leading Neurology and Rare Disease Expert Dr. Nick France Joins FAST Board

More Than a Seat at the Table: FAST’s Role in Shaping the Future of Angelman Syndrome at ASGCT 2025

CAN Spotlight: Kettlebells for Kayleigh Fundraiser in Germany

CAN SPOTLIGHT: Skating Angels Charity Ice Hockey Tournament

MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy ...

FAST Speaks at the 2025 MENA Congress for Rare Diseases

Expanding the Pre-Clinical Research Landscape for Angelman Syndrome

Oak Hill Bio to continue the development of rugonersen, an investigational ASO previously owned by Roch...

CAN Spotlight: Bike 4 Briar Starts May 27th!

FAST-funded researcher highlights the involvement of UBE3A in different neurodegenerative diseases

Progress for Angelman Syndrome Relies on a Strong NIH and FDA

IONIS REVEAL Phase 3 Clinical Trial Update

Exciting Announcement: Launch of Our New Electronic Journal

Community Update: New Insights into Health and Prevention in Angelman Syndrome

The Economic Burden of Caring for Individuals with Angelman Syndrome

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.